StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Candel Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$56.02M. For fiscal 2025 it was -$38.31M. The highest annual figure on record is -$9.07M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.31M–
FY2024Dec 31, 2024-$27.02M–
FY2023Dec 31, 2023-$34.24M–
FY2022Dec 31, 2022-$31.42M–
FY2021Dec 31, 2021-$22.22M–
FY2020Dec 31, 2020-$9.07M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.18M–
Q1 FY2026Mar 31, 2026-$18.04M–
Q4 FY2025Dec 31, 2025-$10.57M–
Q3 FY2025Sep 30, 2025-$10.24M–
Q2 FY2025Jun 30, 2025-$8.89M–
Q1 FY2025Mar 31, 2025-$8.62M–
Q4 FY2024Dec 31, 2024-$5.81M–
Q3 FY2024Sep 30, 2024-$6.57M–
Q2 FY2024Jun 30, 2024-$6.20M–
Q1 FY2024Mar 31, 2024-$8.44M–
Q4 FY2023Dec 31, 2023-$7.42M–
Q3 FY2023Sep 30, 2023-$8.81M–
Q2 FY2023Jun 30, 2023-$7.20M–
Q1 FY2023Mar 31, 2023-$10.82M–
Q4 FY2022Dec 31, 2022-$6.89M–
Q3 FY2022Sep 30, 2022-$9.38M–
Q2 FY2022Jun 30, 2022-$7.10M–
Q1 FY2022Mar 31, 2022-$8.05M–
Q4 FY2021Dec 31, 2021-$5.24M–
Q3 FY2021Sep 30, 2021-$6.89M–
Q2 FY2021Jun 30, 2021-$4.46M–
Q1 FY2021Mar 31, 2021-$5.63M–
Q4 FY2020Dec 31, 2020-$3.42M–
Q3 FY2020Sep 30, 2020-$1.51M–

More Candel Therapeutics figures

See a number that looks wrong?